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The adult mammalian heart has a 
limited capacity for replacing lost tissue 
following injury. Mammalian cardio-
myocytes exit the cell cycle shortly after 
birth, where they undergo a final round 
of DNA synthesis, binucleate, and ter-
minally differentiate.1 In addition, low 
levels of cardiomyocyte turnover in the 
aging heart or following injury seem to be 
mediated mostly by cardiomyocyte divi-
sion.2 Although the neonatal mammalian 
heart can regenerate following injury,3 this 
regenerative capacity is lost by the end of 
the first week of life, with cessation of car-
diomyocyte proliferation. Thus, a deeper 
understanding of mechanisms of cardio-
myocyte cell cycle regulation is a critical 
step toward harnessing the endogenous 
regenerative capacity of the adult heart. 
One of the lasting enigmas in the cardio-
vascular field has been the mechanism, 
and perhaps more importantly the reason, 
for the permanent cell cycle arrest of the 
majority of cardiomyocytes in the post-
natal heart. These questions only become 
more pressing when comparing the injury 
response of the neonatal and adult hearts.
We recently identified a member of 
the TALE homeodomain transcription 
factors, Meis1, as an important regula-
tor of postnatal cardiomyocyte cell cycle 
arrest.4 Although Meis1 mRNA was only 
modestly dysregulated during the narrow 
postnatal regeneration window, we found 
that Meis1 nuclear translocation corre-
sponded to cardiomyocyte cell cycle exit. 
Myocyte-specific Meis1 deletion resulted 
in extension of the postnatal proliferative 
window in the neonatal heart and, to a 
lesser extent, reactivation of myocyte pro-
liferation in the adult heart. In contrast, 
Meis1 overexpression was sufficient to 
reduce cardiomyocyte proliferation and 
inhibition of neonatal heart regeneration.
Progression of eukaryotic cells through 
the cell cycle is controlled by the specific 
activation of a series of CDKs and cyclins.5 
Cyclin/Cdk complexes are regulated by 
2 families of CDK inhibitors, the INK4 
family (including p15, p16, p18, and p19) 
and the CIP/KIP family (including p21, 
p27, and p57). p16INK4a and p21Waf1/Cip1 
are CDK inhibitors that play key roles 
in differentiation and in cell cycle arrest. 
Simultaneous induction of p21Waf1/Cip1and 
p16Ink4a expression cooperatively blocks 
the activation of CDK4/6 and CDK2, the 
key regulators of G1/S and G2/M check-
points. p16 also represses the transcription 
of Cdc20, a key regulator of spindle assem-
bly checkpoint.6 Therefore, simultaneous 
regulation of both p16Ink4a and p21Waf1/
Cip1 will affect cardiomyocyte cell cycle at 
all 3 checkpoints. Examination of Meis1-
null cardiomyocytes showed significant 
downregulation of CDKIs from both the 
Ink (Ink4b/Arf/Ink4a) and the CIP/KIP 
families. We further showed that Meis1 is 
an important transcriptional activator of 
p16Ink4a and p21Cip1/Waf1 in cardiomyocytes.
Despite this exciting new perspec-
tive on transcriptional regulation of car-
diomyocyte cell cycle, there are several 
questions that remain unanswered. First, 
the diverse and complex role that Meis1 
plays in different cell types is likely closely 
related to the local environment as well as 
the expression pattern of Meis1 cofactors. 
We have previously shown that loss of 
Meis1 in hematopoietic stem cells (HSCs) 
results in loss of quiescence and increased 
apoptosis secondary to downregulation 
of the hypoxia master regulators Hif-1α 
and Hif-2α.7,8 While the upregulation of 
Hifs may be critical for the survival of 
HSCs in their hypoxic environment, it 
may have less of an effect in highly oxida-
tive cardiomyocytes under normal condi-
tions, which precludes stabilization of Hif 
transcription factors. In support of this 
notion, we observed no change in apop-
tosis following conditional deletion of 
Meis1 in cardiomyocytes. It is important 
to note here that while Hifs are generally 
degraded in cardiomyocytes under nor-
moxic conditions, myocardial ischemia 
stabilizes Hifs, which, in turn, play a criti-
cal role in stress response of cardiomyo-
cytes. While the transcriptional activity 
of Meis1 in HSCs is closely associated 
with Hoxa9 and Pbx1, the expression pat-
tern of Meis1 cofactors in cardiomyocytes 
appears to be quite different. We did not 
detect significant Hoxa9 or Pbx1 expres-
sion in postnatal cardiomyocytes, while 
the only Meis1 cofactors upregulated > 
2-fold between p1 and p7 (out of 37 Hox 
factors tested) were Hoxa10, Hoxa11, and 
Hoxd12. Intriguingly, these 3 factors, 
along with Hoxa9 and Hoxb13 (which 
was only modestly upregulated), are the 
only confirmed Hox factors that interact 
with Meis1. Therefore, it appears that the 
distinct pattern of expression of Meis1 
cofactors is a critical determinant of its 
activity as redox and cell cycle regulator. 
It will be imperative for future studies to 
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outline the specific role of Meis1 cofactors 
in regulating its diverse expression pattern 
and function and, more importantly, to 
outline the upstream events that regulate 
the specific expression pattern of Meis1 
and its cofactors (Fig. 1).
Other considerations of cardiomyocyte 
cell cycle regulation may relate to specific 
contractile properties of cardiomyocytes. 
A hallmark feature of proliferative neona-
tal cardiomyocytes is sarcomere disassem-
bly, where sarcomeric structures undergo 
degradation and localization to the periph-
ery of the myocytes.3 It is unclear how this 
affects the contractility, or whether the 
isoform of sarcomeric proteins (neonatal 
vs. adult) plays a role in their susceptibility 
to degradation during mitosis.
There is no doubt that the cardiac 
regeneration field has advanced rapidly 
over the past few years. There is now a 
clear view that targeting cardiomyocyte 
cell cycle is a viable therapeutic target, and 
Meis1 may prove to be an important piece 
of that puzzle. Regardless of the specific 
molecular mechanism that mediates post-
natal cell cycle arrest of cardiomyocytes, 
one has to wonder: Why do the majority 
of cardiomyocytes exit cell cycle perma-
nently after birth? Is it a protective mecha-
nism against malignant transformation? Is 
it an inherent property of an incessantly 
contractile organ? The key to unlocking 
the regenerative ability of the adult heart 
may lie in integrating these conceptual 
and mechanistic questions.
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Figure 1. the diverse roles of Meis1. in the bone marrow, Meis1 and its cofactors transcriptionally 
activate Hif-1α and Hif-2α, leading to a reduction in the level of reactive oxygen species and main-
tenance of hematopoietic stem cells (HsC) quiescence (left panel). in the postnatal heart, Meis1 
(and perhaps its cofactors Hoxa10, Hoxa11 and Hoxd12) transcriptionally activates CdKis, thus con-
tributing to the postnatal cell cycle arest of cardiomyocytes (right panel).